Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The National Viral Hepatitis Roundtable is hosting a webinar on hepatitis C among U.S. Veterans
Don’t delay! But be aware of these changes to the 2019 Affordable Care Act marketplace.
Half of people with worse liver function responded well to immunotherapy.
A new report shows people who inject drugs are substantially more likely to contract HIV or HCV post-incarceration.
Researchers analyzed the immunological mechanisms that may drive this difference.
This is according to the large randomized controlled START trial.
Weight-based Harvoni treatment cured almost almost all of a small group of very young people.
One researcher argues that the pharmaceutical industry ought to pay greater heed to such risks during drug development.
Among those who switched their hep B treatment, Vemlidy may also be tied to a higher chance of ALT liver enzyme normalization.
Caring for someone with cirrhosis is hard work and much harder when there is hepatic encephalopathy.
A recent analysis of two studies of AbbVie’s hepatitis C regimen showed good results in this population.
In a recent study of Gilead’s Epclusa (sofosbuvir/velpatasvir), 92 percent of participants were on dialysis and 29 percent had cirrhosis.
This is according to the largest-ever analysis of the treatment cascade among people tested for hep C.
Whether such recurrence is less likely after interferon treatment remains the source of some controversy in the hep C research community.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.